MARKET

BMRN

BMRN

Biomarin Pharmaceutical Inc
NASDAQ
59.45
+0.02
+0.03%
After Hours: 59.80 +0.35 +0.59% 17:45 01/02 EST
OPEN
59.43
PREV CLOSE
59.43
HIGH
59.82
LOW
58.89
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
73.51
52 WEEK LOW
50.76
MARKET CAP
11.42B
P/E (TTM)
22.28
1D
5D
1M
3M
1Y
5Y
1D
BioMarin Acquiring Amicus -- Both Great Companies, Only One Worth Buying Now
Seeking Alpha · 12/30/2025 21:39
Weekly Report: what happened at BMRN last week (1222-1226)?
Weekly Report · 12/29/2025 10:33
Rocket Lab, Micron, And CoreWeave Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 22-Dec. 26): Are the Others in Your Portfolio?
Benzinga · 12/28/2025 13:00
BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight
Seeking Alpha · 12/26/2025 22:07
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2025 Update
Seeking Alpha · 12/26/2025 02:40
Is BioMarin a Bargain After Recent 16.1% Jump and Strong DCF Outlook?
Simply Wall St · 12/25/2025 21:22
Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Wednesday?
Benzinga · 12/23/2025 18:18
What's Going On With BioMarin Stock On Tuesday?
Benzinga · 12/23/2025 18:05
More
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

Webull offers Biomarin Pharmaceutical Inc stock information, including NASDAQ: BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.